Active Biotech and Ipsen in broad partnership for TASQ in uro-oncology

Sweden’s Active Biotech AB (NORDIC: ACTI) and Paris, France-based Ipsen (Euronext: IPN) have entered into a broad partnership to co-develop and commercialize Active Biotech’s investigational compound tasquinimod (TASQ). A global Phase III trial of TASQ in men with metastatic castrate-resistant prostate cancer (CRPC) was recently initiated by Active Biotech and patient recruitment is ongoing.

Under the terms of the agreement, Active Biotech granted Ipsen exclusive rights to commercialize TASQ worldwide, except for North and South America and Japan where Active Biotech retains all commercial and marketing rights. Both companies will co-develop TASQ for the treatment of castrate-resistant prostate cancer, with the possibility to develop TASQ in other cancer indications.

Active eligible to receive 200 million euros